html5-img
1 / 29

CASE CONFERENCE

CASE CONFERENCE. KAREN ESTRELLA PEDS PGY-2 04/28/2011. 16y/o F comes to ER for abdominal pain for 5 days and “rash”. HPI. Abd pain: 5 days, > in flanks, better when sitting No V, N, D Normal stool No dysuria, no vaginal d/c Went to nurse @ school who noted “hard abdomen”

brennan-lopez
Télécharger la présentation

CASE CONFERENCE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CASE CONFERENCE KAREN ESTRELLA PEDS PGY-2 04/28/2011

  2. 16y/o F comes to ER for abdominal pain for 5 days and “rash”

  3. HPI • Abd pain: 5 days, > in flanks, better when sitting • No V, N, D • Normal stool • No dysuria, no vaginal d/c • Went to nurse @ school who noted “hard abdomen” • Rash: small red-purple dot in left breast, later spreading, not painful, not itchy

  4. ROS • Epistaxis • Gums bleeding • “more tired and weak” • Nocturnal sweating • Frequent burping • No wt loss

  5. PE • VS: T 97.8, HR 106, RR 18 BP 95/62, O2 100% Wt: 46.9kg • HEENT: swollen nasal turbinates w/ min bleeding • CV: wnl • Lungs: wnl • Abdomen: + BS, NT, ND, + hard , protuberant upper quadrants, difficult to assess HSM, dull to percusion, no adenopathies • Ext: wnl • Skin: + petechiae in medial lower quadrant of L breast

  6. Differential Dx ?

  7. LabsImaging ?

  8. Labs: • CBC: 88.8<5.3/16.2>21, RBC 2.00 • Coags: 12.1/1.2/27.6 138 100 7 125 3 25 1.5 372 4 27 0.7 6.2 72 • P: 2.6 • UA: turbid, prot: TR, urobilinogen: 5 • Monospot: neg • EBV: + IgG

  9. Labs • Manual differential: • Segm: 3%, Bands: 1%, Lymphs: 89% • atypical Lymph: 3% • Blasts: 3% • RBC morphology: 2+ anysocytosis, hypocromasia • WBC: 2+ smudge cells • Platelets: markedly decrease • Uric Acid: 10.5 • LDH: 3323

  10. Imaging • CXR: normal • Abd Xray:

  11. Dx:Pre-B cell ALL

  12. ALL(Acute Lymphoblastic Leukemia)

  13. Definition: • Malignant disease of BM in which early lymphoid precursors proliferate and replace normal hemotopoietic cells. • Anemia, neutropenia, trombocytopenia • Prolieration in other organs: lymph nodes, spleen, liver • More common cancer in children • 2.8 to 10 cases/100000 • Peak 2-5y/o • > blacks • > boys • Inmunosuppresed sd: Down, ataxia-telangiectasia, neurofibromatosis type 1

  14. Symptoms • Anemia (>75%) • Neutropenia (50%), leukocytosis (20%) • Thrombocytopenia (75%) • Associated with HSM • Fever • Bone pain: aseptic osteonecrosis • Early satiety • Hyperuricemia • Headache: CNS involvement • Lymphadenopathy > 1.5cm • Boys: testicular enlargement • SOB: mediastinal mass

  15. Workup LABORATORY • CBC • Blood smear • Coags: exclude DIC • CMP: LFT • Uric acid • LDH • If febrile: cx IMAGING • CXR • CT SCAN • EKG

  16. Workup • BM biopsy • ALL: >20% lymphoblasts (WHO) in BM and/or peripheral blood

  17. Morphology: • FAB classification on L1, L2, L3 is no longer valid. • Immunophenotype: • Based on CD markers identified by flow cytometry • 70-80% are preB cell: +CD10, CD19, CD20 • 15% are preTcell: +CD2, 3, 4, 5, 7, 8 • Cytogenetics: • hyperdiplody-trisomy 4, 10 (>50): good • Hypodyploidy (<46): poor prognosis • Translocations: t (9;22), t (1;19), t(4;11), and t(8;14)

  18. Prognosis • Cure rate: 80% • With a 5y/o survival in high-risk pts of 65-75% • With a 75-80% of recent dx who are incorporated on clinical trials

  19. Treatment • Induction • Consolidation • Maintenance • CNS

  20. 1. Induction • Place pt on remission : >90% • Drugs: • Vincristine: qwk for 3wks • Corticosteroids: qd • Asparaginase: qd • Doxorrubicin • Success: • Minimal residual disease (MRD) at 2wks and 4 wks (<5% lymphoblasts) • Main complication: tumor lysis sd

  21. Tumor Lysis Syndrome • Rapid leukemic cell lysis after chemotherapy can cause overproduction and overexcretion of uric acid. The precipitation of uric acid in the tubules can lead to oliguric or anuric renal failure. • Risk factors: • Age >10 years • Splenomegaly • Mediastinal mass • Initial white blood cell count >20,000/microL • Labs: • HyperK, hyperP, hypocalcemia, hyperuricemia

  22. 20-25% : + relapse • BM • CNS • Boys: testes • In general: if relapse occurs in <18mo of dx, 5yr prognosis is <21%

  23. 2. Consolidation (intensification) • Soon after MRD. • Goals: Prevent leukemic regrowth, reduce residual tumor burden, prevent drug-resistance in the remaining leukemic cells. • 4-6months • Occasional “pulse therapy” 3. Maintenance • 24-36mo • Drugs: • 6-mercaptopurine + steroids: qd • Metotrexate: qwk • Higher risk of infections: prophylactic Bactrim

  24. 4. CNS • Intrathecal chemotherapy: • Drugs: • Cytarabine • Metotrexate • hydrocortisone

  25. Long term Outcomes • CNS: cognitive impairment, stroke, coordination and fine motor, sensory deficits • Decrease linear growth • Obesity • Cardiotoxicity • Hyperglycemia • Infertility • Increase frequency for secondary malignancies • Brain tumor • AML

  26. In our patient BONE MARROW: Histology: • Hypercellular marrow (> 90%) diffusely infiltrated by blasts. • few scattered megakaryocytes • limited hematopoyesis • a reticulin stain shows mild to moderate diffuse increase in reticulin fibers. Flow cytometry: • 87%: pre B lymphoblasts that express CD9, CD10, CD19, CD22, CD79A, HLA-DR, CD45 and TdT • NEG: CD20, CD34 • 7% mature lymphocytes • 3% grabulocytes Cytogenetic: 46, XX

  27. CHAM course: HD1 • Fever on HD1 : started on Cefepime for 5 days • UA: + yeast: fluconazole • Abd: normal appearing kidneys and bladder HD2: • BM bx, PICC, induction therapy • s/p platelets and PRBC transfusion Treatment: • -vincristine, doxorrubicin, leukovorin, metotrexate, d/c home with f/u

More Related